Cancer-sourced primary human MNCs are isolated from peripheral blood, leukapheresis, or whole blood samples using density gradient separation or red blood cell lysis and cryopreserved in animal component-free CryoStor® CS10 medium. All peripheral blood products are obtained from donors diagnosed with MF using Institutional Review Board (IRB)-approved consent forms and protocols. Additional documentation to meet institutional requirements and high-resolution HLA typing (Class I and Class II alleles and CMV status) are available upon request. Sodium heparin (Na-Hep), ethylenediaminetetraacetic acid (EDTA), or acid-citrate-dextrose solution A (ACDA) is added during collection as an anticoagulant.
Contact firstname.lastname@example.org for donor specifications (BMI category, smoking status, ethnicity, etc.). Donors are screened for HIV-1, HIV-2, hepatitis B, and hepatitis C. Certain products are only available in select territories. For more information, browse frequently asked questions (FAQs) on primary cells.
This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.